Molecular Pathology of Lung and Thoracic Cancers

Dear Colleagues,

Lung cancer is the most common type of thoracic cancer, making the most lethal cancer worldwide. Despite improvements in early detection, surgical treatment, systemic therapy, and radiotherapy, most patients with thoracic cancer are diagnosed at an advanced stage and have a poor prognosis.

Recent advances in molecular profiling technologies have dramatically deepened our understanding of cancer biology, and opened up novel approaches to detect molecular alteration as biomarkers in DNA, RNA, microRNA/long non-coding RNA, proteins, metabolites, exosomes, and circulating tumor cells, using a variety of biospecimens, such as tissue, blood, urine, sputum, and saliva. Molecular biomarkers can be used in multiple clinical settings, including risk assessment, screening, early detection, differential diagnosis, determination of prognosis, therapy selection, prediction of response/toxicity to treatment, and monitoring of reccurence/progression, and have potential to bring about a paradigm shift in current practice and improvement of lung cancer survival.

The scope of this Special Issue is to attract original research as well as review articles describing all aspects of tissue- or biofluid-based molecular biomarkers of lung cancer and other types of thoracic cancer, including thymic tumors and mesothelioma. Potential topics include but are not limited to the following: discovery and/or validation of diagnostic, prognostic, and therapeutic molecular biomarkers; method development for data acquisition and analysis; statistical and bioinformatic approaches to biomarker discovery and development of omics-based signatures; and integration and development of biomarker model.

Dr. Ayumu Taguchi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.